<DOC>
	<DOCNO>NCT00252863</DOCNO>
	<brief_summary>The purpose study determine whether Symbicort dose accord Symbicort Maintenance Reliever Therapy ( SMART ) concept superior standard asthma treatment accord local German treatment guideline .</brief_summary>
	<brief_title>DESOLO - SiT Peri-Launch : A Comparison Symbicort Single Inhaler Therapy Conventional Best Practice Treatment Persistent Asthma Adults</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Budesonide , Formoterol Fumarate Drug Combination</mesh_term>
	<mesh_term>Albuterol</mesh_term>
	<mesh_term>Theophylline</mesh_term>
	<mesh_term>Terbutaline</mesh_term>
	<mesh_term>Formoterol Fumarate</mesh_term>
	<mesh_term>Budesonide</mesh_term>
	<mesh_term>Salmeterol Xinafoate</mesh_term>
	<mesh_term>Fluticasone</mesh_term>
	<mesh_term>Montelukast</mesh_term>
	<mesh_term>Fluticasone Propionate , Salmeterol Xinafoate Drug Combination</mesh_term>
	<criteria>Patients asthma , either wellcontrolled regular therapy combination longacting betaagonists inhale corticosteroid symptomatic therapy inhale corticosteroid alone . Any significant lung disease asthma Any disease might put patient risk participate study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2009</verification_date>
</DOC>